Active Surveillance for Invasive Mold Disease - Four Hospitals, Atlanta, Georgia, 2020-2024. (PubMed, MMWR Surveill Summ) - Jul 29, 2026 - "Among patients with IMD, 65% (n = 292) had at least one MSG host factor that predisposes patients to IMD, and 53% (n = 238) had at least one MSG clinical criterion supporting IMD classification, suggesting that surveillance based only on classic host risk factors or typical clinical findings might miss a substantial proportion of IMD cases.A total of 363 (81%) of 449 patients with IMD received antifungal treatment effective against molds, most commonly isavuconazole (n = 178 [40%]), followed by voriconazole (n = 142 [32%]) and amphotericin B (n = 93 [21%]). Health care providers should be vigilant for IMDs as a life-threatening complication among persons with immunocompromising conditions or critical illness. Continued surveillance could help identify emerging populations at risk for IMD, facilitate earlier recognition and treatment, and support detection of health care-associated outbreaks."
Journal • Allergy • Critical care • Dermatology • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Neutropenia • Novel Coronavirus Disease • Oncology • Otorhinolaryngology • Respiratory Diseases • Transplantation
|
|
Alison M Binder; Anastasia P Litvintseva; Andrea Cool; Brian Jester; Brian Min; Bruno C Rediguieri; Carolyn Mackey; Cordel Phillips; D Joseph Sexton; Dana Goodenough; Donika Grandberry; Eddie Mata; Elizabeth T Sajewski; Hannah Zenas; Jeremy A W Gold; Krupali Patel; Kyle Winston; Lalitha Gade; Lucy S Witt; Luisa F López; Mitsuru Toda; Monica M Farley; Natalie S Nunnally; Nora T Oliver; Saarang Gopinath; Shawn R Lockhart; Stephanie M Pouch; Stepy Thomas
|